We have located links that may give you full text access.
Identification of the First Synthetic Allosteric Modulator of the CB 2 Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief.
Journal of Medicinal Chemistry 2018 July 24
The direct activation of cannabinoid receptors (CBRs) results in several beneficial effects; therefore several CBRs ligands have been synthesized and tested in vitro and in vivo. However, none of them reached an advanced phase of clinical development due mainly to side effects on the CNS. Medicinal chemistry approaches are now engaged to develop allosteric modulators that might offer a novel therapeutic approach to achieve potential therapeutic benefits avoiding inherent side effects of orthosteric ligands. Here we identify the first ever synthesized positive allosteric modulator (PAM) that targets CB2 Rs. The evidence for this was obtained using [3 H]CP55940 and [35 S]GTPγS binding assays. This finding will be useful for the characterization of allosteric binding site(s) on CB2 Rs which will be essential for the further development of CB2 R allosteric modulators. Moreover, the new CB2 R PAM displayed antinociceptive activity in vivo in an experimental mouse model of neuropathic pain, raising the possibility that it might be a good candidate for clinical development.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app